{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:34Z","timestamp":1781646754394,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["73305095007"],"award-info":[{"award-number":["73305095007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["73305095007"],"award-info":[{"award-number":["73305095007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["73305095007"],"award-info":[{"award-number":["73305095007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health\u223cHolland, Topsector Life Sciences & Health","award":["LSHM20106"],"award-info":[{"award-number":["LSHM20106"]}]},{"name":"Health\u223cHolland, Topsector Life Sciences & Health","award":["LSHM20106"],"award-info":[{"award-number":["LSHM20106"]}]},{"name":"Edwin Bouw Fonds"},{"name":"Gieskes-Strijbisfonds"},{"DOI":"10.13039\/100016997","name":"Noaber foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016997","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Houbolt fonds"},{"name":"\u223cHolland, Topsector Life Sciences & Health","award":["LSHM20106"],"award-info":[{"award-number":["LSHM20106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biomarker assessments increasingly inform the diagnostic evaluation and treatment decisions in Alzheimer disease (AD). However, evidence on the impact of amyloid positron emission tomography (PET) disclosure is primarily derived from studies of cognitively unimpaired trial participants with follow-up limited to 18 months. In contrast, long-term implications for individuals with cognitive concerns who seek medical evaluation in memory clinics remain unknown. We aimed to examine the psychosocial and behavioral impact three years after amyloid PET disclosure in individuals presenting with subjective cognitive decline (SCD) at a memory clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In-depth semi-structured interviews were conducted with 17 participants from the Subjective Cognitive Impairment Cohort (SCIENCe) (67\u2009\u00b1\u20097 years; 5 female; 10 amyloid positive) 35\u2009\u00b1\u20094 months post-disclosure. All had SCD at imaging; one had progressed to mild cognitive impairment (MCI) at interview. Verbatim transcripts were analyzed inductively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants\u2019 motivations for testing and long-term adaptation to the results were strongly shaped by cognitive concerns and personal experiences of dementia in relatives. All demonstrated accurate comprehension of their amyloid status. Those with negative scans described immediate relief and reattributed memory lapses to normal aging, while recognizing that the reassurance was provisional. Although positive scans provoked initial shock and fear of deterioration, participants valued information over uncertainty, and over time, fear attenuated as they perceived no rapid decline. Both groups regarded results as meaningful and personally actionable, informing health behavior, life priorities, and preparations for future decline. Fourteen of 17 participants spontaneously mentioned considering options for self-determined end-of-life. Regardless of amyloid status, most participants shared their result with close relatives and friends, some also informed colleagues or acquaintances, while others limited communication to avoid stigma, protect loved ones, or reduce the burden of repeated explanations. Participants valued testing, expressed no regret, and would choose disclosure again.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Three years after disclosure, participants generally had adjusted to living with their imaging result, finding personal meaning and practical engagement without reporting ongoing psychological harm. Some reported residual concerns and uncertainty, irrespective of amyloid status. These findings offer timely guidance for clinicians and patients as biomarker disclosure is more widely incorporated into routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02026-3","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:05:39Z","timestamp":1774605939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline"],"prefix":"10.1186","volume":"18","author":[{"given":"Jetske","family":"van der Schaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie N. C.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietske A. M.","family":"Sikkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardou S. S. A.","family":"van Leeuwenstijn-Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen M. A.","family":"Hendriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelien L.","family":"Bredenoord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette A.","family":"van den Hoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C. A.","family":"Asscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"2026_CR2","doi-asserted-by":"crossref","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79:228\u201343.","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"2026_CR3","doi-asserted-by":"crossref","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","DOI":"10.1002\/alz.13859"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"2026_CR5","doi-asserted-by":"crossref","unstructured":"Cummings JL, Zhou Y, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2025;11:e70098.","DOI":"10.1002\/trc2.70098"},{"key":"2026_CR6","doi-asserted-by":"crossref","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137.","DOI":"10.1038\/s41591-022-02049-x"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13195-024-01494-9","volume":"16","author":"L Quenon","year":"2024","unstructured":"Quenon L, Collij LE, Garcia DV, Lopes Alves I, G\u00e9rard T, Malotaux V, et al. Amyloid-PET imaging predicts functional decline in clinically normal individuals. Alzheimers Res Ther. 2024;16:130.","journal-title":"Alzheimers Res Ther"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1001\/jamaneurol.2015.2875","volume":"72","author":"J Gooblar","year":"2015","unstructured":"Gooblar J, Roe CM, Selsor NJ, Gabel MJ, Morris JC. Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. JAMA Neurol. 2015;72:1484\u201390.","journal-title":"JAMA Neurol"},{"key":"2026_CR9","doi-asserted-by":"crossref","unstructured":"Grill JD, Raman R, Ernstrom K, Sultzer DL, Burns JM, Donohue MC et al. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020;77:1504\u201313.","DOI":"10.1001\/jamaneurol.2020.2734"},{"key":"2026_CR10","doi-asserted-by":"crossref","unstructured":"Ryan MM, Gillen DL, Grill JD. Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. 2021.","DOI":"10.1002\/acn3.51414"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-022-00971-3","volume":"14","author":"J van der Schaar","year":"2022","unstructured":"van der Schaar J, Visser LNC, Bouwman FH, Ket JCF, Scheltens P, Bredenoord AL, et al. Considerations regarding a diagnosis of Alzheimer\u2019s disease before dementia: a systematic review. Alzheimers Res Ther. 2022;14:31.","journal-title":"Alzheimers Res Ther"},{"key":"2026_CR12","doi-asserted-by":"crossref","unstructured":"van der Schaar J, Visser LNC, Ket JCF, Groot C, Pijnenburg YAL, Scheltens P et al. Impact of sharing Alzheimer\u2019s disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data. Alzheimers Dement. 2023;19:5773\u201394.","DOI":"10.1002\/alz.13410"},{"key":"2026_CR13","doi-asserted-by":"crossref","unstructured":"Sato K, Niimi Y, Ihara R, Ikeuchi T, Ishii K, Ito K et al. Immediate reactions to amyloid PET disclosure in Japanese older adults without dementia. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2025;11:e70167.","DOI":"10.1002\/trc2.70167"},{"key":"2026_CR14","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1002\/alz.70121","volume":"21","author":"JE Kim","year":"2025","unstructured":"Kim JE, Ren D, Cohen AD, Lopez OL, Lingler JH. Emotional distress following amyloid PET result disclosure: Heightened among those with cognitive symptoms. Alzheimers Dement. 2025;21:e70121.","journal-title":"Alzheimers Dement"},{"key":"2026_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3233\/JAD-230609","volume":"97","author":"HS Smith","year":"2024","unstructured":"Smith HS, Robinson JO, Levchenko A, Pereira S, Pascual B, Bradbury K, et al. Research Participants\u2019 Perspectives on Precision Diagnostics for Alzheimer\u2019s Disease. J Alzheimers Dis. 2024;97:1261\u201374.","journal-title":"J Alzheimers Dis"},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/alz.13726","volume":"20","author":"M Ritchie","year":"2024","unstructured":"Ritchie M, Salazar CR, Gillen DL, Grill JD. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial. Alzheimers Dement. 2024;20:2508\u201315.","journal-title":"Alzheimers Dement"},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.14283\/jpad.2024.151","volume":"11","author":"FB Ketchum","year":"2024","unstructured":"Ketchum FB, Erickson CM, Basche KE, Chin NA, Eveler ML, Conway CE, et al. Informing Alzheimer\u2019s Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure. J Prev Alzheimer\u2019s Disease. 2024;11:1572\u201380.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"2026_CR18","doi-asserted-by":"crossref","unstructured":"Hendriksen HMA, de Rijke TJ, Fruijtier A, van de Giessen E, van Harten AC, van Leeuwenstijn-Koopman M et al. Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time. Alzheimers Dement. 2024;20:6556\u201365.","DOI":"10.1002\/alz.14148"},{"key":"2026_CR19","doi-asserted-by":"publisher","first-page":"e200265","DOI":"10.1212\/CPJ.0000000000200265","volume":"14","author":"JD Grill","year":"2024","unstructured":"Grill JD, Raman R, Ernstrom K, Wang S, Donohue MC, Aisen PS, et al. Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurol Clin Pract. 2024;14:e200265.","journal-title":"Neurol Clin Pract"},{"key":"2026_CR20","doi-asserted-by":"publisher","first-page":"e2250921","DOI":"10.1001\/jamanetworkopen.2022.50921","volume":"6","author":"C Caprioglio","year":"2023","unstructured":"Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, et al. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline. JAMA Netw Open. 2023;6:e2250921.","journal-title":"JAMA Netw Open"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352.","journal-title":"Alzheimers Dement"},{"key":"2026_CR22","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1212\/WNL.0000000000005863","volume":"91","author":"AC van Harten","year":"2018","unstructured":"van Harten AC, Mielke MM, Swenson-Dravis DM, Hagen CE, Edwards KK, Roberts RO, et al. Subjective cognitive decline and risk of MCI: The Mayo Clinic Study of Aging. Neurology. 2018;91:e300\u201312.","journal-title":"Neurology"},{"key":"2026_CR23","doi-asserted-by":"crossref","unstructured":"Kuhn E, Klinger HM, Amariglio RE, Wagner M, Jessen F, D\u00fczel E et al. SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies. Alzheimers Dement. 2025;21:e14307.","DOI":"10.1002\/alz.14307"},{"key":"2026_CR24","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020;95:e46\u201358.","journal-title":"Neurology"},{"key":"2026_CR25","doi-asserted-by":"crossref","unstructured":"de Rijke TJ, Hendriksen HMA, Fruijtier AD, van Harten AC, van Leeuwenstijn-Koopman MSSA, van de Giessen EM et al. Needs expressed by people with subjective cognitive decline during amyloid PET disclosure consultations: an observational study. Patient Educ Couns. 2025;134:108668.","DOI":"10.1016\/j.pec.2025.108668"},{"key":"2026_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10:76.","journal-title":"Alzheimers Res Ther"},{"key":"2026_CR27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53:378\u201384.","journal-title":"J Nucl Med"},{"key":"2026_CR28","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, Savitcheva I, Farrar G, Salvad\u00f3 G, Collij L, Dor\u00e9 V, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"2026_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62:107\u201315.","journal-title":"J Adv Nurs"},{"key":"2026_CR31","first-page":"238","volume":"8","author":"F Verhage","year":"1965","unstructured":"Verhage F. Intelligence and age in a Dutch sample. Hum Dev. 1965;8:238\u201345.","journal-title":"Hum Dev"},{"key":"2026_CR32","unstructured":"Webster H, Zelinsky M, Rico V, Martinez K, Sankary L. Reconciling recommendations for ethical sharing of biomarker results with Alzheimer\u2019s disease research participants: A systematic review and qualitative synthesis. J Alzheimer\u2019s Disease.0:13872877251392555."},{"key":"2026_CR33","doi-asserted-by":"publisher","first-page":"e12483","DOI":"10.1002\/trc2.12483","volume":"10","author":"CM Erickson","year":"2024","unstructured":"Erickson CM, Ketchum FB, Basche KE, Chin NA, Eveler ML, Clark LR. Communicating Alzheimer\u2019s biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes. Alzheimers Dement (N Y). 2024;10:e12483.","journal-title":"Alzheimers Dement (N Y)"},{"key":"2026_CR34","doi-asserted-by":"crossref","unstructured":"Magana-Ramirez CM, Irizarry-Martinez G, Gillen DL, Grill JD. Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study. Alzheimers Dement. 2024.","DOI":"10.1002\/alz.14077"},{"key":"2026_CR35","doi-asserted-by":"crossref","unstructured":"Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR et al. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014;89:1389\u201396.","DOI":"10.1016\/j.mayocp.2014.05.016"},{"key":"2026_CR36","doi-asserted-by":"crossref","unstructured":"Ott BR, Pelosi MA, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2016;2:23\u20139.","DOI":"10.1016\/j.trci.2015.12.001"},{"key":"2026_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/1467-9566.12731","volume":"40","author":"R Milne","year":"2018","unstructured":"Milne R, Diaz A, Badger S, Bunnik E, Fauria K, Wells K. At, with and beyond risk: expectations of living with the possibility of future dementia. Sociol Health Illn. 2018;40:969\u201387.","journal-title":"Sociol Health Illn"},{"key":"2026_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WAD.0000000000000097","volume":"29","author":"RJ Caselli","year":"2015","unstructured":"Caselli RJ, Marchant GE, Hunt KS, Henslin BR, Kosiorek HE, Langbaum J, et al. Predictive Testing for Alzheimer\u2019s Disease: suicidal ideation in healthy participants. Alzheimer Dis Assoc Disord. 2015;29:252\u20134.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2026_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11673-019-09901-9","volume":"16","author":"G Vanderschaeghe","year":"2019","unstructured":"Vanderschaeghe G, Vandenberghe R, Dierickx K. Stakeholders\u2019 Views on Early Diagnosis for Alzheimer\u2019s Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study. J Bioeth Inq. 2019;16:45\u201359.","journal-title":"J Bioeth Inq"},{"key":"2026_CR40","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2019.0797","volume":"76","author":"EA Largent","year":"2019","unstructured":"Largent EA, Terrasse M, Harkins K, Sisti DA, Sankar P, Karlawish J. Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker. JAMA Neurol. 2019;76:864\u20136.","journal-title":"JAMA Neurol"},{"key":"2026_CR41","doi-asserted-by":"publisher","first-page":"e14623","DOI":"10.1002\/alz.14623","volume":"21","author":"JD Grill","year":"2025","unstructured":"Grill JD, Raman R, Flournoy C, Ernstrom K, Pierce A, Smith A, et al. Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial. Alzheimers Dement. 2025;21:e14623.","journal-title":"Alzheimers Dement"},{"key":"2026_CR42","unstructured":"Regionale Toetsingscommissies Euthanasie. Jaarverslag 2024. 2025."},{"key":"2026_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/15265160701220881","volume":"7","author":"CM Hertogh","year":"2007","unstructured":"Hertogh CM, de Boer ME, Dr\u00f6es RM, Eefsting JA. Would we rather lose our life than lose our self? Lessons from the Dutch debate on euthanasia for patients with dementia. Am J Bioeth. 2007;7:48\u201356.","journal-title":"Am J Bioeth"},{"key":"2026_CR44","doi-asserted-by":"publisher","first-page":"e256841","DOI":"10.1001\/jamanetworkopen.2025.6841","volume":"8","author":"J Wels","year":"2025","unstructured":"Wels J, Hamarat N. Incidence and Prevalence of Reported Euthanasia Cases in Belgium, 2002 to 2023. JAMA Netw Open. 2025;8:e256841\u2013e.","journal-title":"JAMA Netw Open"},{"key":"2026_CR45","doi-asserted-by":"publisher","first-page":"e0229137","DOI":"10.1371\/journal.pone.0229137","volume":"15","author":"EA Largent","year":"2020","unstructured":"Largent EA, Harkins K, van Dyck CH, Hachey S, Sankar P, Karlawish J. Cognitively unimpaired adults\u2019 reactions to disclosure of amyloid PET scan results. PLoS ONE. 2020;15:e0229137.","journal-title":"PLoS ONE"},{"key":"2026_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamaneurol.2017.2954","volume":"75","author":"J Mozersky","year":"2018","unstructured":"Mozersky J, Sankar P, Harkins K, Hachey S, Karlawish J. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults. JAMA Neurol. 2018;75:44.","journal-title":"JAMA Neurol"},{"key":"2026_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/geront\/gnaa113","volume":"61","author":"M Smedinga","year":"2020","unstructured":"Smedinga M, Bunnik EM, Richard E, Schermer MHN. The Framing of Alzheimer\u2019s Disease: Differences Between Scientific and Lay Literature and Their Ethical Implications. Gerontologist. 2020;61:746\u201355.","journal-title":"Gerontologist"},{"key":"2026_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13195-018-0452-1","volume":"10","author":"JD Grill","year":"2018","unstructured":"Grill JD, Cox CG, Harkins K, Karlawish J. Reactions to learning a not elevated amyloid PET result in a preclinical Alzheimer\u2019s disease trial. Alzheimers Res Ther. 2018;10:125.","journal-title":"Alzheimers Res Ther"},{"key":"2026_CR49","doi-asserted-by":"crossref","unstructured":"Grill JD, Cox CG, Kremen S, Mendez MF, Teng E, Shapira J et al. Patient and caregiver reactions to clinical amyloid imaging. 2017.","DOI":"10.1016\/j.jalz.2017.01.001"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02026-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:43Z","timestamp":1781643583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02026-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02026-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Amsterdam UMC (#2023.0737) on October 27th, 2023, and all procedures were carried out in accordance with relevant guidelines and regulations. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS is a recipient of the Alzheimer Nederland InterAct grant (#WE.08-2024-01) and the ZonMw Impact Explorer Dementie (#10510462310005). JS wrote a book for a layman\u2019s audience about the personal impact of dominantly inherited AD, for which she received grants or contracts from Aegon Nederland and Alzheimer Nederland and royalties from Uitgeverij Prometheus. JS is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport.As of 1-11-2025, WF is executive director at Alzheimer Nederland, Amersfoort the Netherlands. Before 1-11-2025, research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Noaber foundation, Pieter Houbolt Fonds, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Eli-Lilly-NL, Fujifilm, Eisai, Combinostics. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). Before 1-11-2025, WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF has been consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France, Nationale Nederlanden Ventures. WF has participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. 2024-2025, WF has been member of the steering committee of phase 3 EVOKE\/EVOKE+ studies (NovoNordisk). In 2025, WF has been member of the steering committee op phase 3 Trontinemab study (Roche). All funding has been paid to Amsterdam UMC. WF was associate editor of Alzheimer, Research & Therapy in 2020\/2021. WF was associate editor at Brain 2021-2025. WF is chair of the Scientific Leadership Group of InRAD. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut.LV has been an invited speaker at an event organized by the Schwabe Group, fees were paid to her institution. Her research has been funded by ZonMW, Alzheimer Nederland, Health~Holland Topsector Life Sciences & Health, Eisai, and Amsterdam Public Health research institute.AH\u2019s research is funded by Alzheimer Nederland, ZonMW amd the ADDF. She was a consultant to Lilly.None of the other authors have conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}